COMMUNIQUÉS West-GlobeNewswire

Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL
11/12/2018
YARDLEY, Pa., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received [...]
CHMP Extends Review Period for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa)
11/12/2018
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines [...]
Transactions in relation to share buyback program
11/12/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Tetra Bio-Pharma Confirms Agreements With Multiple Suppliers
11/12/2018
Quality and volume of Active Pharmaceutical Ingredients (API) ensured ORLEANS, Ontario, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB: TBPMF) a leader in [...]
Santhera's Extraordinary General Meeting Approves Capital Increase
11/12/2018
Pratteln, Switzerland, December 11, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that a vast majority of shareholders approved the ordinary capital increase at today's Extraordinary General Meeting (EGM). [...]
Farmako: Cannabis distributor to become gateway to Europe
11/12/2018
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research [...]
A new scientific publication from AroCell confirming the value of AroCell TK 210 ELISA as a tool in drug discovery and development
11/12/2018
A peer-reviewed article has been published in the journal Nucleosides, Nucleotides and Nucleic Acids, entitled “Doxorubicin effects on leukemia and breast cancer cells in culture on the Thymidine Kinase 1 protein levels [...]
Rule 2.9 Announcement
11/12/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 11 December 2018 [...]
Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid
11/12/2018
PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11 th 2018 - 7 [...]
Néovacs et Centurion Pharma poursuivent leur coopération en lupus suite aux résultats de l'étude de phase IIb avec l'IFNalpha Kinoide
11/12/2018
COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS ET CENTURION PHARMA POURSUIVENT LEUR COOPÉRATION EN LUPUS SUITE AUX RÉSULTATS DE L'ÉTUDE DE PHASE IIB AVEC L'IFNalpha KINOIDE Paris et Boston, [...]
Bone Therapeutics SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA
11/12/2018
Regulated information Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings Gosselies, Belgium, 11 December 2018, 7am CET– BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone [...]
Bone Therapeutics SA : Notification de transparence reçue de la part de S.R.I.W. SA et Sofipôle SA
11/12/2018
Information réglementée Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes Gosselies, Belgique, le 11 décembre, 7h00 CET - BONE THERAPEUTICS (code Euronext Bruxelles et [...]
Pascal Biosciences Announces Year-End Investor Update Webcast
11/12/2018
Advancement of Cannabinoid Cancer Programs and Corporate Review to be Presented Scheduled for Dec. 17, 2018 at 1:30 p.m. Pacific VANCOUVER, British Columbia and SEATTLE, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Pascal [...]
Golden Leaf Holdings announces change in Board of Director composition
11/12/2018
PORTLAND, Ore., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (“Golden Leaf” or the “Company”) (CSE:GLH) (OTCQB:GLDFF), a cannabis company with cultivation, production and retail operations built around [...]
CERESPIR INCORPORATED et le NATIONAL NEUROSCIENCE INSTITUTE – SINGAPOUR annoncent des données positives montrant les effets bénéfiques du composé Itanapraced de CERESPIR au stade clinique dans un modèle LRRK2 de la maladie de Parkinson
11/12/2018
Itanapraced bloque l'expression de LRRK2 et la neurotoxicité à médiation par LRRK2 Itanapraced est prêt à passer à la Phase 2 chez les patients atteints de la maladie de Parkinson avec ou sans mutation génétique NEW [...]
Wright Medical Group N.V. Announces Payment Date and Record Date for CVR Product Sales Milestone Payment
11/12/2018
AMSTERDAM, The Netherlands, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Wright Medical Group N.V. (NASDAQ:WMGI) today announced a contingent value right (CVR) milestone payment of US $1.50 per contingent value right (CVR) payable [...]
BELLUS Health Announces Overnight Marketed Equity Offering
10/12/2018
Not for Distribution to United States Newswire Services or for Dissemination in the United States LAVAL, Quebec, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a [...]
BELLUS Santé annonce un placement d’actions ordinaires négocié entre deux séances boursières
10/12/2018
Ne pas distribuer aux agences de transmission américaines ni diffuser aux États-Unis LAVAL, Québec, 10 déc. 2018 (GLOBE NEWSWIRE) -- BELLUS Santé inc. (TSX : BLU) (« BELLUS Santé » ou la « société »), une société [...]
National Research Corporation Declares Special and Quarterly Dividend
10/12/2018
Lincoln, Nebraska, Dec. 10, 2018 (GLOBE NEWSWIRE) -- image002 National Research Corporation (NASDAQ:NRC) today announced that its Board of Directors has declared a special dividend of fifty cents ($0.50) per share to [...]

Pages